Key Points
- Insider sale: Shattuck Labs insider Arundathy Pandite sold 30,000 shares at an average price of $6.61, totaling $198,300. After the sale, Pandite still held 166,219 shares, down 15.29% from the prior position.
- Recent earnings: The company reported a quarterly loss of $0.13 per share, slightly better than analyst expectations of a $0.14 loss. Analysts currently expect Shattuck Labs to post a full-year loss of $0.51 per share.
- Analyst sentiment: Wall Street sentiment remains broadly positive, with seven Buy ratings and a consensus rating of Moderate Buy. The average price target sits at $13.00, well above the stock’s recent price around $6.67.
Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) insider Abhinav Shukla sold 2,032 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $7.01, for a total transaction of $14,244.32. Following the completion of the sale, the insider directly owned 81,258 shares in the company, valued at approximately $569,618.58. This trade represents a 2.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Shattuck Labs Trading Down 1.2%
Shares of NASDAQ:STTK opened at $6.67 on Friday. The firm's 50 day moving average is $6.61 and its two-hundred day moving average is $4.46. The firm has a market capitalization of $511.46 million, a P/E ratio of -10.59 and a beta of 1.18. Shattuck Labs, Inc. has a 52 week low of $0.71 and a 52 week high of $8.33.
Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. During the same period in the prior year, the business earned ($0.27) earnings per share. Analysts predict that Shattuck Labs, Inc. will post -0.51 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs during the 3rd quarter valued at $29,000. Virtu Financial LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter worth $38,000. AQR Capital Management LLC raised its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after purchasing an additional 31,355 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Shattuck Labs during the second quarter valued at $44,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Shattuck Labs during the third quarter valued at $46,000. Institutional investors own 58.74% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on STTK. Needham & Company LLC initiated coverage on Shattuck Labs in a report on Friday, March 6th. They set a "buy" rating and a $25.00 price target on the stock. HC Wainwright raised their target price on shares of Shattuck Labs from $6.00 to $18.00 and gave the company a "buy" rating in a research note on Monday, April 20th. TD Cowen restated a "buy" rating on shares of Shattuck Labs in a research report on Friday, March 6th. Citigroup upped their price target on shares of Shattuck Labs from $4.00 to $7.00 and gave the stock a "neutral" rating in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded shares of Shattuck Labs from a "hold" rating to a "buy" rating in a research note on Saturday, March 28th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $13.00.
Get Our Latest Stock Analysis on Shattuck Labs
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.
The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
